Boissel et al. [25] analyzed the prognosis of patients with IDH1 mutations and IDH2 mutations in a cohort of 520 adults with AML homogeneously treated in the French Acute Leukemia French Association (ALFA)-9801 and -9802 trials. The gene discussed is IDH1; the disease is acute myeloid leukemia.